Year: 2019

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL) have been selected for oral presentation at the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting, which will be held December 1-6, 2019, in Chicago, IL. Details on the presentations are included below.Date & Time: Monday, December 2, 2019 from 10:10 a.m. to 10:20 a.m. Central TimeSession Title: Nuclear Medicine Series: New PET Tracers for Prostate CancerTitle: The Impact of 18F-DCFPyL PET-CT Imaging on Staging and Clinical Management of Men with De Novo Prostate Cancer: A First Experience within Veterans Healthcare SystemAbstract...

Silmäasema Oyj: Coronaria Oy Announces the Final Amount of Acceptances as of November 21, 2019 in the Public Tender Offer for All Shares Issued by Silmäasema OyjSilmäasema OyjStock Exchange Release25 November at 3:30 p.m. EETCoronaria Oy (“Coronaria” or the “Offeror”) has on September 5, 2019 commenced a mandatory public tender offer to purchase all of the issued and outstanding shares in Silmäasema Oyj (“Silmäasema”) that are not held by the Offeror, Silmäasema or any of its subsidiaries (the “Tender Offer”). The subsequent offer period under the Tender Offer (the “Subsequent Offer Period”) commenced on October 2, 2019 at 9:30 a.m. (Finnish time) and expired on November 21, 2019 at 4:00 p.m. (Finnish time).Based on final information, the shares tendered during the Subsequent Offer Period as of November 21, 2019 represent approximately...

Silmäasema Oyj: Coronaria Oy ilmoittaa 21.11.2019 mennessä vastaanottamiensa hyväksyntöjen lopullisen määrän julkisessa ostotarjouksessa kaikista Silmäasema Oyj:n liikkeeseen laskemista osakkeistaSilmäasema Oyj                Pörssitiedote                      25.11.2019 klo 15.30Lopullisten tietojen perusteella Jälkikäteisen Tarjousajan aikana 21.11.2019 mennessä tarjotut osakkeet edustavat noin 5,52 % kaikista Silmäaseman liikkeeseen laskemista ja ulkona olevista osakkeista ja äänistä. Osakkeet edustavat yhdessä varsinaisena tarjousaikana Ostotarjoukseen tarjottujen ja Tarjouksentekijän markkinoilta muutoin hankkimien Silmäaseman osakkeiden kanssa noin 91,40 % kaikista Silmäaseman liikkeeseen laskemista ja ulkona olevista osakkeista ja osakkeiden tuottamista äänistä.Tarjouksentekijän tarkoituksena on hankkia omistukseensa kaikki Silmäaseman...

TORONTO, Nov. 25, 2019 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV.SRI) (“Sparton” or the “Company“) announced today that it has successfully completed initial reconnaissance work on three Mining Leases (the “Oakes Prospect”) near Hawley Lake in the Matachewan gold mining area of northern Ontario.  See Sparton News Release dated September 25, 2019.HISTORICAL TECHNICAL INFORMATIONThe three Mining Leases (totalling approximately 45 hectares) were historically held by the Sir Harry Oakes Interests in the 1930s and explored by a shallow shaft with lateral workings, several trenches and several short drill holes, which were completed between 1934 and 1936.  They are accessible by all-terrain vehicle and on foot along a 3-km long trail from Ontario Highway 566 between Matachewan and Timmins.Gold mineralization...

Los Angeles, Nov. 25, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Pacific Ventures Group (OTC PINK: PACV) (the “Company”), an investment group concentrating in food, beverage, and alcohol distribution, is pleased to announce today that it has secured financing to acquire a distribution company focused on food, frozen foods and other related products located in Southern California through its subsidiary.Pacific Ventures Group began its due diligence process earlier this year and expects to close the transaction on or before December 15, 2019. The California food distribution company has current annual revenues close to $29 million, serves customers in the state of California and other nearby states. This acquisition complements the Company’s existing food distribution business which is operated by San Diego Farmers Outlet.The...

Closing Scheduled for December 2019Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities availableAltsulin® implantable Sertoli Cells for Type I DiabetesNew technology: Patented, next generation, permeable microcapsules for implantable protein productionBroad Range of Medical Applications for Cell & Gene TherapyMIRAMAR, Fla., Nov. 25, 2019 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (OTCQB: GNBT) is excited to announce that the Company has signed a Stock Purchase Agreement to acquire a 51% controlling interest in ALTuCELL, a privately held biotechnology company, in a stock and cash transaction. With this agreement, Generex gains a broad patent portfolio for cell encapsulation technology and cellular therapy. The transaction is expected to close by...